type in your search and press enter
VBL Therapeutics to Present Data on New Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting
You May Also Like
Loxo Oncology to Announce First Quarter 2018 Financial Results
STAMFORD, Conn., May 01, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical ...
Pivotal Phase 3 Data from CONVERT Study of ALIS in Patients with Treatment-Refractory NTM Lung Disease Caused by MAC Published in American Journal of Respiratory and Critical Care Medicine
--As previously reported, study met primary endpoint of culture conversion (p<0.0001)-- --ALIS under FDA ...
